Cancer genetics is increasingly becoming integrated into the practice of modern medical
oncology. The ability to distinguish a growing proportion of the 5% to 10% of all cancers that …

The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and
Pancreatic focus primarily on assessment of pathogenic or likely pathogenic variants …

Genetic testing for prostate cancer is rapidly growing and is increasingly being driven by
precision medicine. Rates of germline pathogenic variants have been reported in up to 15 …

The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis,
risk stratification and workup, treatment options for localized disease, and management of …

PURPOSE To provide precise age-specific risk estimates of cancers other than female
breast and ovarian cancers associated with pathogenic variants (PVs) in BRCA1 and …

PURPOSE Germline testing (GT) is a central feature of prostate cancer (PCA) treatment,
management, and hereditary cancer assessment. Critical needs include optimized …

Background BRCA1 and BRCA2 mutations have been associated with prostate cancer
(PCa) risk but a wide range of risk estimates have been reported that are based on …

Background Germline mutations in BRCA1/2 and ATM have been associated with prostate
cancer (PCa) risk. Objective To directly assess whether germline mutations in these three …

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer
Early Detection provide recommendations for prostate cancer screening in healthy men who …

Multiple genetic loci confer susceptibility to breast and ovarian cancers. We have previously
developed a model (BOADICEA) under which susceptibility to breast cancer is explained by …